Neuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture.

Spread the love


. 2021 Feb 12;6(1):40-47.

doi: 10.1089/can.2019.0102. eCollection 2021.

Affiliations

Item in Clipboard

Jungnam Kim et al. Cannabis Cannabinoid Res. .

Abstract

Introduction: Reports on the neurotoxic and neuroprotective effects of cannabidiol (CBD) have not been in complete accord, showing different and somewhat contradictory results depending upon the brain cell types and experimental conditions employed. This work systematically examines the neuroprotective capability of CBD against oxidative stress (i.e., hydrogen peroxide [H2O2]) as well as its toxicity profile in the in vitro culture platform of primary hippocampal neurons. Materials and Methods: The low cell-density (100 neurons per mm2) culture was used for analyzing the viability and morphology of neurons at a single-cell level with a confocal laser-scanning microscope (CLSM). Primary neurons were obtained from the hippocampal tissues of embryonic day-18 (E18) Sprague-Dawley rat pups and treated with CBD (0.1-100 μM) and/or H2O2 (0.1-50 μM) at 1 DIV (days in vitro). Results: The lethal concentration 50 (LC50) value (the concentration causing 50% cell death) of CBD was calculated to be 9.85 μM after 24 h of incubation, and that of H2O2 was 2.46 μM under the same conditions. The neuroprotection ratio of CBD against H2O2 ([H2O2]=10 μM) was 2.40 with 5 μM of CBD, increasing the cell viability to 57% from 24%. The CLSM analysis suggested that the cell-death mechanisms were different for CBD and H2O2, and CBD did not completely rescue the morphological alterations of primary hippocampal neurons caused by H2O2, such as neurite degeneration, at least in the in vitro neuron culture. Conclusion: Although CBD showed both neurotoxic and neuroprotective effects on hippocampal neurons in the in vitro setting, the use of low-concentrated (i.e., 5 μM) CBD, not causing toxic effects on the neurons, significantly rescued the neurons from the oxidative stress (H2O2), confirming its neuroprotection capability.

Keywords: cannabidiol; cell culture; hydrogen peroxide; neuroprotection; primary hippocampal neurons.

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.

FIG. 1.

Neurotoxicity of CBD to primary hippocampal neurons. The neurons were treated with CBD (0, 0.1, 1, 3, 5, 10, 15, 30, 50, and 100 μM) at 1 DIV, and the CLSM images were taken after 24 h of incubation. (a) CLSM images of hippocampal neurons (green: live, red: dead). (b) A graph of %viability versus log[CBD]. LC50 was calculated as the concentration at which the %viability was 50%. Data are expressed as mean±SE of n=3, each with three replicates. CBD, cannabidiol; CLSM, confocal laser-scanning microscope; DIV, days in vitro; LC50, lethal concentration 50; SE, standard error.

FIG. 2.

FIG. 2.

Effects of CBD on cell adhesion and morphology. Representative CLSM images of primary hippocampal neurons in CBD (10 μM) or 0.1% DMSO, after staining F-actin (green), cytoplasm (red), and nuclei (blue). DMSO, dimethyl sulfoxide.

FIG. 3.

FIG. 3.

Neurotoxicity of H2O2 to primary hippocampal neurons. The neurons were treated with H2O2 (0, 0.1, 1, 3, 5, 7, 10, 30, and 50 μM) at 1 DIV, and the CLSM images were taken after 24 h of incubation. (a) CLSM images of hippocampal neurons with different H2O2 concentrations. (b) A graph of %viability versus log[H2O2]. LC50 was calculated as the concentration at which the %viability was 50%. Data are expressed as mean±SE of n=3 each with three replicates. H2O2, hydrogen peroxide.

FIG. 4.

FIG. 4.

Neuroprotective effect of CBD against H2O2. Hippocampal neurons were treated with H2O2 (10 μM) and CBD (0, 0.1, 1, 2, 3, and 5 μM) at 1 DIV and incubated for 24 h. (a) CLSM images of primary hippocampal neurons after 24-h incubation with CBD and H2O2. (b) A graph of PR[CBD] versus the CBD concentration. Data are expressed as the mean %viabilities of the [+H2O2][+CBD] cases divided by the mean %viability of the [+H2O2][−CBD] case, repeated n=4 cultures, each with three replicates. The 0.1% DMSO was used for 0-μM CBD.

FIG. 5.

FIG. 5.

High-magnification CLSM images of hippocampal neurons after 24-h treatment of (middle) H2O2 (10 μM), and (right) H2O2 (10 μM), and CBD (5 μM). The cells were stained in green (F-actin), red (β-tubulin III), and blue (nuclei).

References

    1. Reekie TA, Scott MP, Kassiou M. The evolving science of phytocannabinoids. Nat Rev Chem. 2017;2:0101
    1. Koppel BS, Brust JC, Fife T, et al. . Systematic review: efficacy and safety of medical marijuana in selected neurological disorders. Neurology. 2014;82:1556–1563 – PMC PubMed
    1. Scuderi C, Filippis DD, Iuvone T, et al. . Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23:597–602 – PubMed
    1. Iuvone T, Esposito G, Filippis DD, et al. . Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther. 2009;15:65–75 – PMC PubMed
    1. Hayakawa K, Mishima K, Fujiwara M. Therapeutic potential of non-psychotropic cannabidiol in ischemic stroke. Pharmaceuticals. 2010;3:2197–2212 – PMC PubMed

Schaka

Related Posts

Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial

Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol

Watching the Legalization Wave in Summer 2021: Week in Review

Effects of topiramate on the association between affect, cannabis craving, and cannabis use in the daily life of youth during a randomized clinical trial

Signez la pétition !!!

 

845 signatures

Pétition ASBL Cannabis Belgique

Pourquoi une pétition ?

Nous sommes des personnes qui en avons assez de devoir aller dans la rue et avoir affaire à des réseaux criminels sans savoir où cela va nous conduire par après.

Nous sommes des personnes ayant des maladies, qui pour certaines sont rares, et utilisant pour médication le cannabis sous diverses formes (CBD,THC,THCv,CBDa,,,) sous l'accord de notre médecin.

Nous sommes des personnes responsables et honnêtes qui avons une vie épanouie et sans problèmes de vie ou sociaux.

Nous avons également une passion pour la plante de cannabis en elle-même et la cultiver est notre bonheur. De plus, nous pouvons nous soigner avec notre médication sans avoir peur des produits ou autres additifs contenus dans une plante que l'on peut trouver autre part.

Nous souhaitons pouvoir avoir notre médicament dans les normes de la santé publique, car un cannabis sain aide à réduire les frais de santé parfois conséquents pour la collectivité et le malade lui-même.

Nous sommes également des personnes responsables avec un rôle dans la société qui en avons assez d’être considérés comme des « hippies ou autres drogués », nous avons juste choisi notre médication et celle-ci a apporté les preuves de son efficacité dans le monde.

Nous connaissons déjà les produits dérivés comme le CBD et le THC que nous maîtrisons pour nous aider dans notre maladie « Je précise que nous ne sommes pas médecin et que nous nous basons sur 20 ans d’expérience médicale du cannabis des membres de notre ASBL et l'avis du médecin de famille ».

Nous désirons simplement ne plus nous cacher, et pouvoir aider les autres personnes le souhaitant.

Nous somme soucieux des ados et de la prévention à leur égard. Effectivement, nous sommes les acteurs parfaits pour répondre aux questions qu’ils se posent vu notre expérience cannabique et, de plus, nous pourrons leur expliquer les risques qu’ils encourent en achetant du cannabis dans la rue.

Le projet complet peut être demandé via mail " info@mcb.care " et sur le site internet : " http://mcb.care "

@ASBL McB

**votre signature**

Partagez avec vos amis

Articles récents

Catégories